Informed Consent
Item
1. ability to understand and willingness to sign a written informed consent document.
boolean
C0021430 (UMLS CUI [1])
Breast Carcinoma
Item
2. subject must have histologically confirmed breast cancer.
boolean
C0678222 (UMLS CUI [1])
Neoadjuvant Chemotherapy Scheduled | Secondly Operative Surgical Procedure Scheduled
Item
3. subject must be scheduled to receive neoadjuvant chemotherapy followed by surgery for their standard cancer care. treatment decisions will be made by the treating surgeon and the medical oncologist.
boolean
C0600558 (UMLS CUI [1,1])
C3665472 (UMLS CUI [1,2])
C0205539 (UMLS CUI [1,3])
C0205436 (UMLS CUI [2,1])
C0543467 (UMLS CUI [2,2])
C0205539 (UMLS CUI [2,3])
Gender | Age
Item
4. females at least 18 years of age.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Karnofsky Performance Status
Item
5. karnofsky at least 60% at time of screening.
boolean
C0206065 (UMLS CUI [1])
Life Expectancy
Item
6. life expectancy of greater than 6 months.
boolean
C0023671 (UMLS CUI [1])
Organ function | Bone Marrow function
Item
7. subject must have normal organ and marrow function (as defined below) within 30 days of study enrollment:
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
White Blood Cell Count procedure
Item
leukocytes at least 3,000/microl
boolean
C0023508 (UMLS CUI [1])
Absolute neutrophil count
Item
absolute neutrophil count at least 1,500/microl
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets at least 100,000/microl
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
total bilirubin equal or less than 1.0 mg/dl
boolean
C1278039 (UMLS CUI [1])
Aspartate aminotransferase measurement
Item
ast(sgot) no greater than 2.5 x institutional upper limit of normal
boolean
C0201899 (UMLS CUI [1])
Alanine aminotransferase measurement
Item
alt (sgpt) no greater than 2.5 x institutional upper limit of normal
boolean
C0201836 (UMLS CUI [1])
Creatinine measurement, serum
Item
creatinine equal or less than 1.4 mg/dl
boolean
C0201976 (UMLS CUI [1])
Blood urea nitrogen measurement
Item
bun equal or less than 20 mg /dl
boolean
C0005845 (UMLS CUI [1])
Effects of FLT Fetus Unknown | Childbearing Potential Contraceptive methods | Gender Contraceptive methods | Hormonal contraception | Contraception, Barrier | Sexual Abstinence
Item
8. the effects of flt on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. a screening urine hcg will be administered in the nuclear medicine to women of childbearing potential before each flt scan and pregnant women will not be accepted as subjects in this study.
boolean
C1704420 (UMLS CUI [1,1])
C0206795 (UMLS CUI [1,2])
C0015965 (UMLS CUI [1,3])
C0439673 (UMLS CUI [1,4])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C2985296 (UMLS CUI [4])
C0004764 (UMLS CUI [5])
C0036899 (UMLS CUI [6])
Chemotherapy | Therapeutic radiology procedure | Nitrosoureas | Mitomycin | Adverse event Due to Pharmaceutical Preparations | Recovery Lacking
Item
1. subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
C0002475 (UMLS CUI [4])
C0877248 (UMLS CUI [5,1])
C0678226 (UMLS CUI [5,2])
C0013227 (UMLS CUI [5,3])
C2004454 (UMLS CUI [6,1])
C0332268 (UMLS CUI [6,2])
Karnofsky Performance Status
Item
2. subject with a karnofsky score of below 60.
boolean
C0206065 (UMLS CUI [1])
Pregnancy | Breast Feeding To be stopped
Item
3. pregnant women are excluded from this study. flt pet has potential for teratogenic effects. because there are potentially unknown risks for adverse events in nursing infants secondary to treatment of the mother with flt, breastfeeding should be discontinued if the mother is imaged with flt and may not resume for 48 hours after the flt imaging.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Nucleoside Analogs | Anti-Retroviral Agents
Item
4. subjects taking nucleoside analog medications such as those used as antiretroviral agents.
boolean
C1579410 (UMLS CUI [1])
C0599685 (UMLS CUI [2])